Open public hearings
This article was originally published in The Tan Sheet
Executive Summary
Individuals who wish to present during open public hearings at advisory committee meetings are not required to disclose financial ties, FDA says in a draft guidance published in the Federal Register Feb. 15. Although disclosure is encouraged, panelists should not ask further questions about a potential link, but may ask for further details on scientific content, the draft guidance adds...
You may also be interested in...
Open Public Hearing Speakers Should Disclose Financial Conflict – Comments
FDA should permit advisory committee members and voting consultants to question open public hearing speakers about their potential conflicts of interest during advisory committee meetings, according to the consumer advocacy group Public Citizen
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.